Oxford Cancer Analytics was formed in 2018 and
won the 2019 Oxford University
All-Innovate competition. The founders came together with a single goal - to save lives. DEcancer.AI relies only on the biomarkers found in a standard blood test, known as a
liquid biopsy to diagnose patients with lung cancer at an earlier stage than is typical for conventional methods. This product would have the potential to
save patients money, protect them from the painful invasive testing and harmful radiation, and detect lung cancer while it can
still be treated.